CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Mirtazapine +1 moredrug
Likely dose
Mirtazapine 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165541
NCT01165541Phase 2Completed
CompareCT.gov

An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers

Dartmouth-Hitchcock Medical Center·interventional·Posted Jul 20, 2010·Updated Apr 9, 2018

In Brief

A Phase 2 clinical trial evaluating Mirtazapine and Quetiapine fumarate extended release (Quetiapine XR) for Alcohol Dependence. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

The purpose of the study is to test whether taking two medicines (quetiapine and mirtazapine) is better for helping people to decrease drinking than taking one medicine alone (quetiapine).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.0 years ago

Interventions

Mirtazapinedrug

mirtazapine (7.5-45mg)

Quetiapine fumarate extended release (Quetiapine XR)drug

Quetiapine fumarate extended release 50-400mg/d